Penumbra (NYSE:PEN) and Spectral AI (NASDAQ:MDAI) Head to Head Survey

Spectral AI (NASDAQ:MDAI) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Insider and Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 13.7% of Spectral AI shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Spectral AI and Penumbra, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1	0	1	1	2.67
Penumbra	0	14	3	0	2.18

Spectral AI currently has a consensus price target of $4.00, indicating a potential upside of 193.04%. Penumbra has a consensus price target of $367.07, indicating a potential upside of 14.26%. Given Spectral AI’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Spectral AI is more favorable than Penumbra.

Risk & Volatility

Spectral AI has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Valuation and Earnings

This table compares Spectral AI and Penumbra”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65 million	2.24	-$7.57 million	($0.35)	-3.90
Penumbra	$1.40 billion	9.02	$177.69 million	$3.97	80.92

Penumbra has higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Spectral AI and Penumbra’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-74.56%	N/A	-79.07%
Penumbra	10.06%	10.39%	8.09%

Summary

Penumbra beats Spectral AI on 10 of the 15 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc. is a medical diagnostic technology company focused on using artificial intelligence and advanced imaging to support earlier, more objective assessment of wound healing. The company develops predictive diagnostic systems intended to help clinicians evaluate wounds and make treatment decisions. Its principal product is the DeepView System, a noninvasive imaging and artificial intelligence platform designed to assess burn wounds and predict the likelihood that injured tissue will heal without surgical intervention.

About Penumbra

Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.